- Slower than anticipated sales uptake of Ximluci® in Europe
- Uncertainty about US market approval for Ximluci®
- Dependence on distribution partners
- Financing of clinical studies for pre-clinical products
- Potential delays in the production process of product candidates
- Need to secure agreements with commercialization partners
- Managing growth as a relatively small company
- Financing risk
XBRANE BIOPHARMA AB
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, XBRANE BIOPHARMA AB disclosed greenhouse gas emissions of 9 tonnes of eCO2 (Scope 2). By scope: Scope 2: 9 tonnes of eCO2. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
9 tonnes of eCO2 (Scope 2)
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 9 tonnes of eCO2 |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 9 tonnes of eCO2 (Scope 2) |
| 2022 | 10 tCO2e/year (Scope 2) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- Reduced non-recyclable waste in the office by 20%
🎯 Climate & Sustainability Targets
🔜 Short-term
- Support STADA in growing sales of Ximluci® in Europe
- FDA approval and launch of Ximluci® in the US
- Launch pre-filled syringe for Ximluci® in Europe in Q1 2025
📅 Medium-term
- Scale up BIIB801 manufacturing and sell clinical material to Biogen Inc.
- Out-license Xdivane™ to a global commercialization partner
- Achieve positive cash flow in Q1 2025
🌱 ESG Focus Areas
Health equalityCredibilityResponsible acting in societyAttractive employer